Demonstrates dexmedetomidine reduces allodynia and sleep disruption in male mice, indicating therapeutic potential for chronic pain and sleep disorders.
Chronic pain and sleep disorders frequently co-occur and exacerbate each other, yet the neural mechanisms underlying this comorbidity remain poorly understood. Here, we found that hyperactivity of GABAergic neurons in the dorsal division of the lateral septum (LS GABA ) drives both pain-like behavior and sleep disruption induced by spared nerve injury (SNI) in male mice. We showed that systemic or local application of dexmedetomidine (DEX), with known sedative and analgesic properties, reduces LS GABA hyperactivity via α 2 A adrenergic receptor activation, alleviating pain-like behavior and sleep disruption. LS GABA can project onto the glutamatergic and GABAergic neurons in the lateral preoptic area (LPO), respectively. The LS GABA →LPO Glu circuit and the LS GABA → LPO GABA circuit contribute to mechanical allodynia and sleep disruption, respectively. Furthermore, LS α 2 A adrenergic receptor plays an important role in DEX-regulated activity of LPO GABA and LPO Glu . Taken together, these findings reveal a shared neural substrate for chronic pain and sleep disorders and establish DEX as a potential treatment for this comorbidity through selective modulation of LS GABA -driven circuits.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: